Daniel K. Nomura

This paper develops a stereoselective covalent inhibitor of PAX8, a key ovarian cancer driver, showing its ability to reduce PAX8 abundance and suppress its transcriptional program.

This paper develops an optimized covalent handle targeting RNF126 to create molecular glue degraders, showing improved selectivity and reduced cytotoxicity compared to a fumarate-based handle.

This paper introduces TRACERs, small-molecule drugs that silence transcription factors in cancer by recruiting repressor complexes, showing efficacy against ER and AR in breast and prostate cancer.

This study identifies methionine metabolism and the NOP2 methyltransferase as critical for MYC-driven liver tumorigenesis, suggesting NOP2 as a potential therapeutic target.

This study identifies ZD-1-186, a non-degradative molecular glue that rewires BCL6 proximity to suppress MYC and induce tumor-suppressive genes in lymphoma cells.

This paper demonstrates that ER membrane proteins can be degraded via cytosolic E3 ligase recruitment, bypassing ERAD and relying on VCP-mediated ubiquitin chain cleavage.

This study shows that A20 regulates macrophage metabolism by restricting nitric oxide production, which restores bioenergetic balance and prevents pro-inflammatory phenotypes.

This paper develops second-generation acyl silane photoaffinity probes for cellular chemoproteomic profiling, showing improved labeling properties compared to existing diazirine-based probes.

This paper identifies a sulfinyl aziridine compound that selectively degrades MYC by targeting specific residues in its intrinsically disordered regions, demonstrating the potential of chiral small molecules for targeting undruggable proteins.

The paper shows that gap junctions between breast cancer cells and adipocytes transfer cAMP, activating lipolysis in the tumor microenvironment to support tumor growth.

This paper identifies covalent modulators that target and degrade IRF5 and IRF8, key inflammatory transcription factors, with TH-B10 showing potent and selective degradation of IRF8.

This study shows that low-dose inorganic arsenic exposure reprograms macrophage polarization, increasing tumor-promoting activity and altering immune responses in a sex-dependent manner.

This paper identifies a covalent degradative handle that can be transplanted onto various protein-targeting ligands to induce degradation of their targets, enabling modular degrader design.

This paper identifies a covalent compound EN1441 that selectively degrades AR and AR-V7 in androgen-independent prostate cancer cells by targeting an intrinsically disordered cysteine.

This study identifies a covalent ligand, EN171, that enhances 14-3-3 interactions with transcription factors like ER, YAP, and TAZ, inhibiting their activity and demonstrating its use in heterobifunctional molecules to sequester nuclear substrates.

This paper identifies a covalent degrader, EN83, that targets and degrades β-catenin by covalently binding to four cysteine residues, demonstrating a strategy to overcome the 'undruggable' challenge of transcription factors.

This study identifies a covalent handle that enables the degradation of multiple protein targets when appended to protein-targeting ligands.

This study identifies a covalent recruiter against SKP1 for PROTAC-based protein degradation, demonstrating its efficacy in degrading BRD4 and androgen receptor via the SCF complex.

This study identifies a covalent recruiter targeting DDB1 for PROTAC applications, enabling degradation of BRD4 and androgen receptor.

This study engineered microbial strains to produce three C4 chemicals with ~95% theoretical yield by altering gene loci that control carbon flow.

The paper uncouples glucose sensing from metabolism in yeast by using a cellobiose pathway, revealing new regulatory mechanisms for ATP management and energy homeostasis.